Experimental Mis-Splicing Assessment and ACMG/AMP-Guided Classification of 47 ATM Splice-Site Variants
Authors:
- Inés Llinares-BurguetILInés Llinares-Burguet
- Lara Sanoguera-MirallesLara Sanoguera-Miralles
- Elena Bueno-MartínezEBElena Bueno-Martínez
- Ada Esteban-SanchezAEAda Esteban-Sanchez
- Daniel Romano-MedinaDRDaniel Romano-Medina
- Lobna Ramadane-MorchadiLRLobna Ramadane-Morchadi
- Alicia García-ÁlvarezAGAlicia García-Álvarez
- Pedro Pérez-SeguraPPPedro Pérez-Segura
- Doug F. EastonDEDoug F. Easton
- Peter DevileePeter Devilee
- Maaike P. G. VreeswijkMVMaaike P. G. Vreeswijk
- Miguel de la HoyaMHMiguel de la Hoya
Open Access
- 12 January 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 765
Abstract
Pathogenic germline variants in the ATM gene are associated with a 20–30% lifetime risk of breast cancer. Crucially, a relevant fraction of loss-of-function variants in breast cancer susceptibility genes disrupts pre-mRNA splicing. We aimed to perform splicing analysis of ATM splice-site variants identified in the large-scale sequencing project BRIDGES (Breast Cancer After Diagnostic Gene Sequencing). To this end, we bioinformatically selected 47 splice-site variants across 17 exons that were genetically engineered into three minigenes and assayed in MCF-7 cells. Aberrant splicing was observed in 38 variants. Of these, 30 variants, including 7 missense, yielded no or negligible expression of the minigene full-length (mgFL) transcript. A total of 69 different transcripts were characterized, 48 of which harboured a premature termination codon. Some variants, such as c.2922-1G>A, generated complex patterns with up to 10 different transcripts. Alternative 3′ or 5′ splice-site usage was the predominant event. Integration of ATM minigene read-outs into the ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology)-based specifications for the ATM gene enabled the classification of 30 ATM variants as pathogenic or likely pathogenic and 9 as likely benign. Overall, splicing assays provide key information for variant interpretation and the clinical management of patients.Keywords
Funding Information
- Instituto de Salud Carlos III (PI23/00047)
- Instituto de Salud Carlos III (PI24/00267)
- European Commission (634935)
- Consejería de Educación, Junta de Castilla y León (Programa Estratégico, Escalera de Excelencia Instituto de Biomedicina y Genética Molecular (IBGM) de Valladolid)
This publication has 66 references indexed in Scilit:
- Minigene‐based splicing analysis and ACMG/AMP‐based tentative classification of 56 ATM variantsThe Journal of Pathology, 2022
- Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic VariantsJAMA Oncology, 2022
- Splicing predictions, minigene analyses, and ACMG‐AMP clinical classification of 42 germline PALB2 splice‐site variantsThe Journal of Pathology, 2021
- Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM GeneJAMA Oncology, 2021
- Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelinesHuman Mutation, 2020
- Mis‐splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assaysThe Journal of Pathology, 2019
- Associations Between Cancer Predisposition Testing Panel Genes and Breast CancerJAMA Oncology, 2017
- Neurodegeneration in ataxia‐telangiectasia: Multiple roles of ATM kinase in cellular homeostasisDevelopmental Dynamics, 2017
- Functional Classification of BRCA2 DNA Variants by Splicing Assays in a Large Minigene with 9 ExonsHuman Mutation, 2014
- Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variantsHuman Mutation, 2012